Metis Therapeutics Launches With $86 Million Series A Financing To Transform Drug Discovery And Delivery With Machine Learning And Artificial Intelligence

METiS Therapeutics debuts today with $86 million Series A financing to harness artificial intelligence (AI) and machine learning to redefine drug discovery and delivery and develop optimal therapies for patients with serious diseases. PICC PE and China Life led the financing and were joined by Sequoia Capital China, Lightspeed, 5Y Capital, FreeS Fund and CMBI Zhaoxin Wuji Fund. The financing will be used to advance the company’s pipeline of novel assets with high therapeutic potential and the continued development of its AI-driven drug discovery and delivery platform.